
Summit Therapeutics (SMMT) Stock Forecast & Price Target
Summit Therapeutics (SMMT) Analyst Ratings
Bulls say
Summit Therapeutics is viewed favorably because the clinical data for ivonescimab continue to strengthen, with HARMONi-2 improving to an OS HR of 0.73 at 234 deaths from 0.777 at 157 deaths and showing median OS of 30.75 versus 22.57 months, which eases concerns about the earlier survival readout. The company’s case is further supported by the competitive context, since its efficacy profile is being weighed against sac-TMT + pembrolizumab, which posted a 0.35 PFS HR and 70.2% ORR versus 0.51 and 50.0% for ivonescimab. Although sac-TMT’s early OS HR of 0.55 at 87 deaths still needs maturation, HARMONi-3’s final PFS/interim OS in 2H26 is the key global test.
Bears say
Summit Therapeutics is viewed negatively because its ivonescimab program still lacks the mature, global evidence needed to justify premium expectations, while the company’s China data are showing less durability than early headlines implied. H-6’s PFS hazard ratio worsened from 0.60 at 10.28 months to 0.72 at 17.02 months, H-2 still shows immature OS with an HR of about 0.78, and H-3 did not accelerate regulatory timing despite added interim review. The outlook is further pressured by Merck’s sac-TMT and MK-2010 options, which limit differentiation and raise combination toxicity concerns, with Grade ≥3 TRAEs of 29.4% versus 15.6% in HARMONi-2 and 55.3% versus 31.4% with sac-TMT plus pembrolizumab.
This aggregate rating is based on analysts' research of Summit Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Summit Therapeutics (SMMT) Analyst Forecast & Price Prediction
Start investing in Summit Therapeutics (SMMT)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Summit Therapeutics (SMMT) Forecast
Summit Therapeutics (SMMT) Analyst Forecast & Price Prediction
Start investing in Summit Therapeutics (SMMT)
Order type
Buy in
Order amount
Est. shares
0 shares